Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bone Evaluation in HIV-positive women over 40 who Switch from TDF + 3TC/FTC + NNRTI to Triumeq

Next Previous
Trial Profile

Bone Evaluation in HIV-positive women over 40 who Switch from TDF + 3TC/FTC + NNRTI to Triumeq

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Efavirenz; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate; Emtricitabine/tenofovir disoproxil fumarate; Etravirine; Lamivudine; Nevirapine; Rilpivirine; Tenofovir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms BESTT women's

    • Most Recent Events

    • 01 Apr 2022 Results assessing bone mineral density, kidney function and participant-reported outcome measures in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG, published in the HIV Medicine
    • 11 Mar 2020 Status changed from recruiting to completed as per results presented at the 27th Conference on Retroviruses and Opportunistic Infections
    • 11 Mar 2020 Results presented at the 27th Conference on Retroviruses and Opportunistic Infections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top